AIM
CUE icon

Aigen Investment Management’s Cue Biopharma CUE Stock Holding History

Aigen Investment Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-657
Closed -$297K – 823
2020
Q3 		$297K Buy
+657
New +$379K 0.04% 543

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Aigen Investment Management's CUE Position: Q4 2020 in Review

Aigen Investment Management sold out of Cue Biopharma (CUE) in Q4 2020, closing a stake of 657 shares — an estimated $297K sold.

Aigen Investment Management first reported a position in CUE in Q3 2020 and held it in 1 quarter. The position peaked at $297K in Q3 2020. 97 funds tracked by Wall St. Rank hold CUE as of Q4 2020.

  • Aigen Investment Management reported no remaining Cue Biopharma position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 657 Cue Biopharma shares in Q4 2020, an estimated $297K.
  • Aigen Investment Management first reported a position in Cue Biopharma in Q3 2020 and held it in 1 quarter.
  • Aigen Investment Management's Cue Biopharma position peaked at $297K in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.